Receptol Science in Detail
RECEPTOL® contains the Nano-Informational Peptides (RADHA108) and Proline-Rich Polypeptides (PRPs), derived from bovine Colostrum, which helps in strengthening the body’s own immune system against diseases in a natural way. The nano-polypeptides have been known for long for their antiviral, anti-inflammatory and immune enhancing properties.
However, the molecular mechanism of their action in conjunction with low molecular weight nano-peptides was not known until Dr. Theodore Damodar Singh, an Applied Biochemist from University of California Irvine and Founder Director, Chaitanya Healthcare, India and Dr. Pawan Saharan, Chief Scientific Officer and Founder Director, Chaitanya Healthcare and Biomix Network Ltd., India identified and studied a series of NanoInformational Peptides (RADHA1081-100) from Bovine Colostrum.
The fusion of viral particles with human white blood cells occurs with the aid of glycoprotein epitopes on the viral wall. The informational proteins (RADHA1081-100) in RECEPTOL® have been shown to mitigate cell fusion. The RADHA1081-100 series of molecules may dock on the glycoprotein receptors of the viral surface mimicking their receptors on the cell surfaces and thus block the virus entry into the immune cells.
One of the Immunomodulatory action of RECEPTOL® is to stimulate the maturation of immature thymocytes into either helper or suppressor T cells, depending on the need of the body at a given time. Helper T cells present antigens (such as viral protein) to B lymphocytes, which in turn produce antibodies to that antigen6 . Helper T cells also help produce memory T cells which retain the memory of an antigen in order to expedite the production of antibodies in the event the antigen is reencountered in the future .
Suppressor T cells, on the other hand, have been shown to deactivate other lymphocytes after an infection has been cleared to avoid damage to healthy tissues8 . RECEPTOL® may also promote growth and differentiation of B cells in response to an infection and the differentiation and maturation of macrophages and monocytes. The activity of Natural Killer (NK) cells, cytotoxic cells of the innate immune system, is increased by up to 5-fold by RECEPTOL® . RECEPTOL® may modulate the cytokine system as well. Its constituents have been shown to stimulates the production of a wide range of cytokines, including the pro-inflammatory cytokines Tumor Necrosis Factor – Alpha (TNF-α) and Interferon Gamma (INF–γ) and anti-inflammatory cytokines Interleukin – 6 and – 10 .
The constituents of RECEPTOL® may function as a molecular signaling device which works through receptors on target cell surfaces to initiate or suppress the production of specific proteins. This property is not species specific2 ; and hence the constituents of RECEPTOL® derived from bovine Colostrum may work as effectively in humans too like the PRP of human Colostrum. There are no known side effects or drug interactions with the constituents of Colostrum, and it may be taken safely by patients of all ages. In an experimental in vitro system, the constituents of RECEPTOL® have been shown to effectively block HIV infection of cells.
References
1. Saharan P. Mammalian Colostrum derived Nanopeptides for broad spectrum viral and recurrent infection with a method of isolation thereof, US Granted product patent (#8518454 B2).
2. Saharan P. Mammalian colostrum derived Nanopeptide for broad spectrum viral 7 recurrent infections with method of isolation thereof, Singapore patent (Patent No. 172793)
3. Saharan P. Mammalian Colostrum Derived Nanopeptides For Broadspectrum Viral And Recurrent Infections With A Method Of Isolation Thereof, South Africa Patent (Patent No. # 2011/04687)
4. Mammalian Colostrum Derived Nanopeptides For Broadspectrum Viral And Recurrent Infections With A Method Of Isolation Thereof, Europe (Application no. EP 09827010.1)
5. Saharan P. Mammalian Colostrum derived nanopepteides for broad spectrum viral and recurrent infection with a method of isolation thereof. Patent submitted to Indian Patent office, 2007.
6. Saharan P. Rajadhyaksha G., An Interventional Phase III Accelerated Study to Determine The Efficacy and Safety of RECEPTOL® Oral Spray (Radha108 nanopeptides derived from Bovine Colostrum) Used to Delay the ART Treatment in HIV Positive Patients With Multiple Symptoms as a Stand-Alone Mono Therapy with comparative data of HIV patients on ART (could be an Answer to Swine flu, Ebola?), publishing in BMJ open
7. Saharan P. Rajadhyaksha G., A study on Novel Broad Spectrum Antiviral & new generation Immunomodulator (Radha108) Nanopeptides from Bovine Colostrum for the Treatment of recurrent infection in HIV, Publishing in Journal of AIDS.
8. Saharan P., Singh T., Safety and efficacy Clinical Trial of RECEPTOL*: New Nanobiotechnology based immunomodulator in HIV therapy. Unpublished Patented data (2005- 2006).
9. World Health Organization. Progress on global access to HIV antiretroviral therapy: a report on "3 by 5" and beyond. 2006.
10. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, Serwadda D, Lutalo T, Nalugoda F, Sewankambo N, Kiduggavu M, Wawer M, Gray R. Mortality in HIV-infected and 11 uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquire Immune Defic Snyder 2006;41(4):504-8.
11. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364(9441):1236-43.
12. Taha TE, Dallabetta GA, Canner JK, Chiphangwi JD, Liomba G, Hoover DR, Miotti PG. The effect of human immunodeficiency virus infection on birth weight and infant and child mortality in urban Malawi. Int J Epidemiol 1995; 24(5):102 1
3. Wieczorec Z., Zimecki M., Spiegel K., Lisowski J., Janusz M., Differentiation of T-Cells from immature precursors: identification of a target cell for a proline-rich polypeptide (PRP) Archivum immunological therapies experimentalists (Warszawa) 37(3-4):313-322(1989).
14. Kubis A., Marcinkowska E., Janusz M., Lisowski J. Studies on mechanism of action of a prolinerich polypeptide complex (PRP): Effect on stage of cell differentiation peptides 26(11) : 2188- 2192 (2005).
15. Modulation of 4HNE-mediated 20(2):125-134 (2003).
16. Zibiocka A., Janusz M., Rybka K., Wirkus – Romanowska I. Kupryszewski G., Lisowski J. Cytoline inducing activity of a proline-rich polypeptide (PRP) from ovine colostrum and its active nanopeptide fragment analogs. European Cytokine Network 12(3) :462-467 (2001). 16
17. Fernadez- ortega C. Dubed M. Ruibal O. Vilarruba OL. Menendez de San Pedro JC. Navea L. Ojeda M. Arana MJ. Inhibition of in vitro HIV infection by dialyzable leucocyte extracts, Biotherapy 9(1-3)33-40 (1996).
18. Zimecki M,Staroscik K, Janusz M, Lisowski J, Wieczorek Z. The inhibitory activity of proline rich polypeptide on the immune response to polyvinyl pyrrolidone (PVP). Arch Immunol Ther Exp (Warsz)1983;31(6):895-903.
19. Julius MH, Janusz M, Lisowski J. A colostral protein that induces the growth and differentiation of resting B lymphocytes. J Immunol, 1988; 140(5):1366-371.
20. Boldogh I, Liebenthal D, Hughes TK, Juelich TL, Georgiades JA, Kruzel ML, Stanton GJ. Modulation of 4HNE-mediated signaling by a proline-rich polypeptides from ovine colostrum. J Mol Neurosci. 2003;20(2):125-134.
21. Pizza G, Chiodo F, Colangeli V, Gritti F, Raise E, Fudenberg HH. Preliminary observations using HIV-specific transfer factor in AIDS. Biotherapy. 1996;9(1-3):4-47.
22. Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C, Mugyenyi P, Cao H. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005; 174(7):4407-4414.
23. Shi M, Hao S, Chan T, Xiang J. CD4+ T cells stimulate memory CD8+ T cell expansion via acquired pMHC I complexes and costimulatory molecules, and IL-2 secretion. J Leuco Biol, 2006; 80(6):1354-1363.
24. Granitov, VM et al. Usage of RECEPTOL in treatment of HIV – Infected patients. Russian Journal of HIV AIDS and Related Problems 2002, 1, 79-80. 25. Lawrence HS, Borkowsky W:Transfer factor:Current status and future prospects,Biotherapy9:1:5,1996.